Filing Details

Accession Number:
0001127602-24-014811
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-09 17:15:23
Reporting Period:
2024-05-08
Accepted Time:
2024-05-09 17:15:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492422 Apellis Pharmaceuticals Inc. APLS Pharmaceutical Preparations (2834) 271537290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657720 Pascal Deschatelets C/O Apellis Pharmaceuticals, Inc.
100 Fifth Avenue, 3Rd Floor
Waltham MA 02451
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-08 78,907 $4.31 1,194,890 No 4 M Direct
Common Stock Disposition 2024-05-08 56,335 $42.15 1,138,555 No 4 S Direct
Common Stock Disposition 2024-05-08 22,472 $42.85 1,116,083 No 4 S Direct
Common Stock Disposition 2024-05-08 100 $44.03 1,115,983 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-05-08 78,907 $0.00 78,907 $4.31
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
108,622 2027-08-22 No 4 M Direct
Footnotes
  1. This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
  2. This transaction was executed in multiple trades at prices ranging from $41.575 - $42.570. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $42.575 - $43.545. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This stock option was granted on 08/21/2017 and is fully vested.